AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of claims in the application:

LISTING OF CLAIMS:

1. (previously presented): 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate.

2. (previously presented): A crystal of 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate.

3. (previously presented): The crystal according to claim 2, which has X-ray powder diffraction spectrum shown in Fig 3.

4. (previously presented): The crystal according to claim 2, which has diffraction angle 2θ at 8.96, 12.70, 13.69, 14.98, 15.74, 16.38, 17.63, 18.98, 19.71, 20.49, 21.37, 22.26, 22.88, 23.76, 24.70, 25.79 and 26.57 on X-ray powder diffraction spectrum.

5. (currently amended): The crystal according to claim 2, which has infrared resonance spectrum shown in Fig. 4.

6. (previously presented): The crystal according to claim 2, which has absorption of infrared resonance spectrum at 1652, 1595, 1549, 1220, 1168, 1141, 1115, 1034, 790, 766, 548, 533 and 522 cm^{-1}.

7. (previously presented): A process for the preparation of 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate, which comprises reacting 8-(3-pentylamino)-2-methyl-3-(2-chloro-4-methoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine with methanesulfonic acid.

8. (previously presented): A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

9. (currently amended): ~~The~~ A pharmaceutical composition comprising 1% or more of the crystal according to claim 2, and a pharmaceutically acceptable carrier.

10. -23. (canceled).

24. (previously presented): 8-(3-Pentylamino)-2-methyl-3-(2-chloro-4-rnethoxyphenyl)-6,7-dihydro-5H-cyclopenta[d]pyrazolo[1,5-a]pyrimidine methanesulfonate which is superior in thermal stability.